Effects of omega-3 fatty acids and coenzyme Q10 on cardiovascular risk in chronic renal failure

心脏病是澳大利亚的主要死因之一。慢性肾功能衰竭（CRF）患者由于高血压（高血压）、血脂异常、炎症和氧化应激增加的共存，心血管风险增加。一种方法可能是用非药物措施（如营养和生活方式因素）补充CRF的药物治疗。在这方面，ω-3脂肪酸在治疗CRF及其相关并发症方面具有巨大的临床潜力。Omega-3脂肪酸降低血压和血管壁弹性，它们改善血脂，减少血液凝块的倾向，减轻炎症和氧化应激。辅酶Q10是一种抗氧化剂，在细胞功能中起着关键作用。它可以改善血压，血管和心脏功能，以及葡萄糖控制。有人提出，补充鱼油和辅酶Q10形式的ω-3脂肪酸的联合方法的影响，将对轻度至中度慢性肾衰竭患者的血压和心脏病风险产生有益的复合效应。在拟议的研究中，患者将在3周的基线期内接受医学和生化评估，之后他们将被分配每天用4g胶囊鱼油或安慰剂补充正常饮食。在每组中，他们将进一步被分配服用辅酶Q10胶囊（200 mg）或安慰剂胶囊。在8周结束时重复所有测量。

Heart disease is one of the main causes of death in Australia. People with chronic renal failure (CRF) are at increased cardiovascular risk due to the coexistence of hypertension (high blood pressure), blood lipid abnormalities, and increased inflammation and oxidative stress. One approach may be to complement drug treatment of CRF with non-drug measures such as nutrition and lifestyle factors. In this regard, omega-3 fatty acids have great clinical potential in the treatment of CRF and its associated complications. Omega-3 fatty acids reduce blood pressure and blood vessel wall elasticity, they improve blood fats, reduce the tendency of blood to clot, and attenuate inflammation and oxidative stress. Coenzyme Q10 is an antioxidant that plays a critical role in cellular function. It improves blood pressure, blood vessel and heart function, and glucose control. It is proposed that the impact of a combined approach of supplementation of omega-3 fatty acids given as fish oils and coenzyme Q10, will lead to beneficial composite effects on blood pressure and heart disease risk in patients with mild-to-moderate chronic renal failure. In the proposed study, patients will undergo medical and biochemical assessment during a 3-week baseline period, after which they will be allocated to either supplement their normal diet with either 4g of encapsulated fish oil or placebo per day. Within each of these groups they will be further assigned to take coenzyme Q10 capsules (200mg) or placebo capsules. All measurements will be repeated at the end of 8 weeks.